Medtronic plc. (NYSE:MDT) CRT Devices Touted For Cost Saving Credentials

Medtronic Plc

Data presented at Europace 2017 indicates that Medtronic plc. Ordinary Shares (NYSE:MDT)’s cardiac resynchronization therapy (CRT) has the potential to lower healthcare costs while improving therapy in heart failure patients. Trials carried in three countries showed that the use of CRT therapies in combination with proprietary AdaptivCRT and EffecticeCRT algorithms can extend life expectancy by an average of four months.

Story continues below

Improved Therapy Delivery

Economic analysis of Medtronic defibrillators demonstrated an increase in projected device longevity of up to nine years. Improved device longevity should lead to fewer device replacements allowing patients to enjoy significant cost savings in the long run.

Medtronic uses AdaptivCRT algorithm in its systems to adjust the way devices pace patient’s hearts in a minute by minute evaluation. The proprietary algorithm has already proved to be effective in reducing the odds of a 30-day heart failure readmission. The algorithm also considerably reduces the risk of people developing atrial Filtration AF.

“It is exciting to see that this technology helps increase the amount of CRT delivered during atrial fibrillation. Many patients with heart failure experience AF at some point, and we now have the ability to better address the individual needs of these difficult-to-treat patients.”,” said Giuseppe Boriani, Professor of Cardiology at the University of Modena.

Medtronic Growing AF Solution Segment

The new data according to, Kweli Thompson, general manager of CRT business underscores Medtronic commitment to providing treatment that not only improves patient’s quality of life but are also affordable. The results caps yet another milestone as the company continues to build its atrial fibrillation solution segment.

The approval of Medtronic’s implantable cardioverter defibrillator has since been eclipsed by positive results on the company’s upcoming Reactive ARP therapy. Reactive ATP is a painless pacing therapy found in the company’s cardiac resynchronization therapy (CRT) devices.

Based on the analysis of 8,800 patients, Medtronic’s ATP therapy successfully reduced progression of AF in patients implanted with cardiac devices. The company is now set to be a major player on the treatment AF, a condition that affects over 33 million people worldwide.

Medtronic stock was down by 0.19% in Tuesday’s trading session to end the day at $88.82 a share

An ad to help with our costs